ArticleFrontiers in pharmacology2022
Flecainide and risk of skin neoplasms: Results of a large nested case-control study in Spain and Denmark.
Carlen Reyes, Luz M León-Muñoz, Andrea Pistillo, Sigrún Alba Jóhannesdóttir Schmidt, Kasper Bruun Kristensen, Diana Puente, Ana LLorente-García, Consuelo Huerta-Álvarez, Anton Pottegård, Talita Duarte-Salles
Open access · goldAbstract read
In one paragraphArticle in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 75% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 6 institutions in 2 countries.
Carlen ReyesFundació Institut Universitari per a la Recerca a L'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Luz M León-MuñozDelegation for the National Plan on Drugs, Ministry of Health, Madrid, Spain.
Andrea PistilloFundació Institut Universitari per a la Recerca a L'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Sigrún Alba Jóhannesdóttir SchmidtDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Kasper Bruun KristensenClinical Pharmacology, Pharmacy, and Environmental Medicine, Institute of Public Health, University of Southern Denmark, Odense, Denmark.
Diana PuenteFundació Institut Universitari per a la Recerca a L'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Ana LLorente-GarcíaPharmacoepiemiology and Pharmacovigilance Division, Spanish Agency for Medicines and Clinical Devices-AEMPS, Madrid, Spain.
Consuelo Huerta-ÁlvarezDepartment of Public Health & Maternal and Child Health, Faculty of Medicine. Complutense University of Madrid-UCM, Madrid, Spain.
Anton PottegårdDepartment of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Talita Duarte-SallesFundació Institut Universitari per a la Recerca a L'Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.
Institut Universitari d'Investigació en Atenció Primària Jordi Gol · ESAarhus University Hospital · DKAgencia Española de Medicamentos y Productos Sanitarios · ESMinistry of Health · ESUniversidad Complutense de Madrid · ESUniversity of Southern Denmark · DK
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
case-control studiesdatabaseflecainidemelanomaskin neoplasm
Identifiers
PMID36618916
PMCPMC9822716
OpenAlexW4312173957
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390